Covered recipient · General Payments record
HIVA BASTANMEHR
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2020–2024
$924.70
- Reported across 30 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $440.73 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $159.95 | 5 |
| GlaxoSmithKline, LLC. | $74.45 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $51.30 | 2 |
| Agios Pharmaceuticals, Inc. | $30.40 | 1 |
| ABBVIE INC. | $29.12 | 1 |
| Exact Sciences Corporation | $25.15 | 1 |
| Merck Sharp & Dohme Corporation | $24.06 | 1 |
| Lilly USA, LLC | $23.60 | 1 |
| PFIZER INC. | $22.70 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $29.12 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103289225 | CMS |
| Agios Pharmaceuticals, Inc. | $30.40 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149642042 | CMS |
| Amgen Inc. | $19.68 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117198875 | CMS |
| Amgen Inc. | $74.39 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111525898 | CMS |
| Amgen Inc. | $22.80 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111525894 | CMS |
| Amgen Inc. | $23.71 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117198877 | CMS |
| Amgen Inc. | $19.37 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111525896 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.99 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117993722 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.31 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117993724 | CMS |
| Exact Sciences Corporation | $25.15 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114586968 | CMS |
| GlaxoSmithKline, LLC. | $25.88 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116591887 | CMS |
| GlaxoSmithKline, LLC. | $26.15 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116335825 | CMS |
| GlaxoSmithKline, LLC. | $22.42 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116567544 | CMS |
| Lilly USA, LLC | $23.60 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135027466 | CMS |
| Merck Sharp & Dohme LLC | $24.06 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141905704 | CMS |
| PFIZER INC. | $22.70 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131236563 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2020 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.